AGC Biologics Expands its Heidelberg Facility to Develop its pDNA...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

AGC Biologics Expands its Heidelberg Facility to Develop its pDNA and mRNA Manufacturing Capability

Pharma Tech Outlook | Wednesday, September 29, 2021

The news comes about a month after AGC Biologics completed the successful acquisition of a facility in Longmont, Colorado, which allowed the company to expand its C&GT capabilities into the United States.

FREMONT, CA: AGC Biologics, a chief global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), recently expanded its Heidelberg facility to improve manufacturing capacity for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.

By installing an extra GMP manufacturing line, AGC Biologics is increasing its current 100L and 1,000L manufacturing capacities for various biologics projects. A novel GMP cleanroom for mRNA development and production, a new process development lab for microbial protein and cell and gene therapy (C>) projects, and increased storage capacity are also part of the expansion. AGC Biologics will be able to fulfill the expanding demands of the rapidly developing C> industry thanks to its improved capabilities. The additional capabilities of the plant will be completely operational in 2023.

"This investment helps strengthen our existing pDNA capabilities and supports our entry into the mRNA space," said Patricio Massera, Chief Executive Officer, AGC Biologics. "With the global pDNA and mRNA markets experiencing record growth, we are focused on ensuring our facilities worldwide offer innovative services that meet the needs of therapeutics developers."

This is the newest in a series of investments made by AGC Biologics to extend its offerings and global footprint this year. In August, AGC Biologics broke work on a new multipurpose facility in Copenhagen, Denmark, that will expand the company's global capacity. The news comes about a month after AGC Biologics completed the successful acquisition of a facility in Longmont, Colorado, which allowed the company to expand its C&GT capabilities into the United States. The company also extended its Cell and Gene Therapy Facility in Milan, Italy, earlier this year, adding more capacity and viral vector suspension capabilities.

"These new capacities will help strengthen our Heidelberg facility," remarked Dieter Kramer, Site Head, AGC Biologics Heidelberg. "We are looking forward to this location having a greater impact on the services AGC Biologics offers to our industry."

Weekly Brief

Read Also